Overview
Caribou Biosciences Q3 net loss of $27.5 mln, with licensing revenue at $2.2 mln
R&D expenses decreased due to reduced clinical trial activities and workforce reduction
Company maintains $159.2 mln in cash for funding operations into 2H 2027
Outlook
Caribou expects to fund operations into 2H 2027 with current resources
Result Drivers
Research and development expenses were $22.4 million for the three months ended September 30, 2025, compared to $30.4 million for the same period in 2024.
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Licensing and Collaboration Revenue
$2.20 mln
Q3 Net Income
-$27.55 mln
Q3 Basic EPS
-$0.30
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Caribou Biosciences Inc is $8.50, about 73.6% above its November 11 closing price of $2.24
Press Release: ID:nGNX6gXqxl
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
